The Diagnostic Value of the Fibrinogen-to-Albumin Ratio (FAR) in Migraine Attacks
Fibrinogen-to-Albumin Ratio in Migraine Attacks
DOI:
https://doi.org/10.5281/zenodo.21267893Keywords:
Migraine Disorders, Inflammation, Blood Coagulation DisordersAbstract
Objective: Migraine is a common primary headache disorder that negatively affects quality of life. Its etiology is not fully understood, but inflammation and hypercoagulation are involved in its pathogenesis. Several recent studies have identified the fibrinogen-to-albumin ratio (FAR) as an important biomarker of inflammation and procoagulant states. This study aimed to determine the value of FAR in the diagnosis of migraine attacks.
Methods: This study included 50 patients diagnosed with migraine attacks and a control group of 50 healthy individuals. Demographic data of both groups were recorded. Clinical features such as disease duration, attack frequency, attack type (with or without aura), and accompanying symptoms were recorded in migraine patients. Migraine attack severity was determined using the Visual Analog Scale (VAS). Blood fibrinogen, albumin, and FAR values were analyzed in the migraine group during the attack and compared with the control group.
Results: The mean age of the migraine group was 36.26 ± 9.87 years (41 female), and that of the control group was 35.22 ± 11.11 years (28 female). No significant difference was found in fibrinogen (p=0.098) or albumin (p=0.492) values in migraine patients. No significant difference was found in FAR (p=0.161). No significant relationship was found between FAR and disease duration (p=0.984) or attack frequency (p=0.978). In the receiver operating characteristic (ROC) analysis, FAR was not a significant predictor of migraine attack diagnosis (AUC=0.435, p=0.263).
Conclusion: In this cohort, FAR was not a useful biomarker for diagnosing migraine attacks. However, given the limited sample size, larger studies are needed before its diagnostic value can be definitively excluded.
References
Ashina M. Migraine. N Engl J Med. 2020;383(19):1866-1876. doi:10.1056/NEJMra1915327
GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459-480. doi:10.1016/S1474-4422(18)30499-X
Andreou AP, Edvinsson L. Mechanisms of migraine as a chronic evolutive condition. J Headache Pain. 2019;20(1):117. doi:10.1186/s10194-019-1066-0
Dodick DW. Migraine. Lancet. 2018;391(10127):1315-1330. doi:10.1016/S0140-6736(18)30478-1
Charles A. Migraine: a brain state. Curr Opin Neurol. 2013;26(3):235-239. doi:10.1097/WCO.0b013e32836085f4
Ashina M, Hansen JM, Do TP, Melo-Carrillo A, Burstein R, Moskowitz MA. Migraine and the trigeminovascular system—40 years and counting. Lancet Neurol. 2019;18(8):795-804. doi:10.1016/S1474-4422(19)30185-1
Ashina M, Terwindt GM, Al-Karagholi MAM, et al. Migraine: disease characterisation, biomarkers, and precision medicine. Lancet. 2021;397(10283):1496-1504. doi:10.1016/S0140-6736(20)32162-0
Peck J, Urits I, Zeien J, et al. A comprehensive review of over-the-counter treatment for chronic migraine headaches. Curr Pain Headache Rep. 2020;24(5):19. doi:10.1007/s11916-020-00852-0
Smitherman TA, Burch R, Sheikh H, Loder E. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache. 2013;53(3):427-436. doi:10.1111/head.12074
Goldberg LD. The cost of migraine and its treatment. Am J Manag Care. 2005;11(2 suppl):S62-S67.
Tietjen GE, Collins SA. Hypercoagulability and migraine. Headache. 2018;58(1):173-183. doi:10.1111/head.13044
Bithell TC. Blood coagulation. In: Wintrobe's Clinical Hematology. Vol 1. Lea & Febiger; 1993:568-570.
Tousoulis D, Papageorgiou N, Androulakis E, Briasoulis A, Antoniades C, Stefanadis C. Fibrinogen and cardiovascular disease: genetics and biomarkers. Blood Rev. 2011;25(6):239-245. doi:10.1016/j.blre.2011.05.001
Reinhart WH. Fibrinogen—marker or mediator of vascular disease? Vasc Med. 2003;8(3):211-216. doi:10.1191/1358863x03vm494ra
Infusino I, Panteghini M. Serum albumin: accuracy and clinical use. Clin Chim Acta. 2013;419:15-18. doi:10.1016/j.cca.2013.01.005
Karahan O, Acet H, Ertaş F, et al. The relationship between fibrinogen to albumin ratio and severity of coronary artery disease in patients with STEMI. Am J Emerg Med. 2016;34(6):1037-1042. doi:10.1016/j.ajem.2016.03.003
Gao Y, Zong C, Yao Y, et al. Elevated fibrinogen-to-albumin ratio correlates with incident stroke in cerebral small vessel disease. J Inflamm Res. 2024;17:4331-4343. doi:10.2147/JIR.S466879
Çiçekli E, Sayan S, Kotan D. Availability of fibrinogen/albumin ratio in MS attack. Mult Scler Relat Disord. 2022;60:103674. doi:10.1016/j.msard.2022.103674
Bilge A, et al. Fibrinogen/albumin ratio in patients with pulmonary embolism. Phoenix Med J. 2023;5(2):67-70. doi:10.38175/phnx.1202390 (bağımsız doğrulanamadı)
Stovner LJ, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193-210. doi:10.1111/j.1468-2982.2007.01288.x
Bjørk MH, Stovner LJ, Nilsen BM, Stjern M, Hagen K, Sand T. The occipital alpha rhythm related to the "migraine cycle" and headache burden: a blinded, controlled longitudinal study. Clin Neurophysiol. 2009;120(3):464-471. doi:10.1016/j.clinph.2008.11.018
Brighina F, Bolognini N, Cosentino G, et al. Visual cortex hyperexcitability in migraine in response to sound-induced flash illusions. Neurology. 2015;84(20):2057-2061. doi:10.1212/WNL.0000000000001584
Tabakcı MM, Gerin F, Sunbul M, et al. Relation of plasma fibrinogen level with the presence, severity, and complexity of coronary artery disease. Clin Appl Thromb Hemost. 2017;23(6):638-644. doi:10.1177/1076029616629210
Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005;3(8):1894-1904. doi:10.1111/j.1538-7836.2005.01365.x
Ferrara M, Capozzi L, Bertocco F, Ferrara D, Russo R. Thrombophilic gene mutations in children with migraine. Hematology. 2012;17(2):115-117. doi:10.1179/102453312X13221316478010
Martínez-Sánchez P, Martínez-Martínez M, Fuentes B, et al. Migraine and hypercoagulable states in ischemic stroke. Cephalalgia. 2011;31(16):1609-1617. doi:10.1177/0333102411427599
Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ. 2009;339:b3914. doi:10.1136/bmj.b3914
Hirano K, Takashima S, Dougu N, et al. Study of hemostatic biomarkers in acute ischemic stroke by clinical subtype. J Stroke Cerebrovasc Dis. 2012;21(5):404-410. doi:10.1016/j.jstrokecerebrovasdis.2011.08.013
Tietjen GE, Khubchandani J, Herial N, et al. Migraine and vascular disease biomarkers: a population-based case-control study. Cephalalgia. 2018;38(3):511-518. doi:10.1177/0333102417698936
Kurth T, Ridker PM, Buring JE. Migraine and biomarkers of cardiovascular disease in women. Cephalalgia. 2008;28(1):49-56. doi:10.1111/j.1468-2982.2007.01467.x
Guo Y, Rist PM, Sabater-Lleal M, et al. Association between hemostatic profile and migraine: a Mendelian randomization analysis. Neurology. 2021;96(20):e2481-e2487. doi:10.1212/WNL.0000000000011931
Sheinenzon A, Shehadeh M, Michelis R, Shaoul E, Ronen O. Serum albumin levels and inflammation. Int J Biol Macromol. 2021;184:857-862. doi:10.1016/j.ijbiomac.2021.06.140
Yazar HO, Yazar T, Aygün A, Kaygisiz Ş, Kirbaş D. Evaluation of simple inflammatory blood parameters in patients with migraine. Ir J Med Sci. 2020;189(2):677-683. doi:10.1007/s11845-019-02136-y
Jacobsen LM, Winsvold BS, Romundstad S, Pripp AH, Holmen J, Zwart JA. Urinary albumin excretion as a marker of endothelial dysfunction in migraine sufferers: the HUNT study, Norway. BMJ Open. 2013;3(8):e003268. doi:10.1136/bmjopen-2013-003268
Yılmaz G, Sürer H, Üçler S, İnan L, Yücel D. Plasma malondialdehyde levels in migraine with and without aura. Turkiye Klinikleri J Med Sci. 2004;24(4):309-315.
Halliwell B. Albumin—an important extracellular antioxidant? Biochem Pharmacol. 1988;37(4):569-571. doi:10.1016/0006-2952(88)90126-8
López-Gentili LI, Garate G, Riveros D, Ameriso SF. Antiphospholipid antibodies in patients with vestibular manifestations: a study of 16 cases. Rev Neurol. 2003;36(2):112-117.
Calabrese S, Giansante C, Oselladore F, Benedetti A, Mitri E. Evaluation of platelet function and coagulation in deafness and sudden vestibular disorders. Minerva Med. 1983;74:1357-1363.
Fattori B, Nacci A, Ghilardi PL, Bruschini L, Matteucci F, Ursino F. Acute peripheral vertigo: involvement of the hemostatic system. Int Tinnitus J. 2003;9(2):124-129.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2026 Derya Bayrak, Buket Yılmaz, Ramazan Şencan, Betül Özenç, Pelin Yenilmez Yeşildaş
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Avicenna Anatolian Journal of Medicine operates under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
